Radiometallated peptides targeting guanylate cyclase C and the urokinase-type plasminogen activator receptor

Future Oncology

Volumn 6, Issue 8, 2010, Pages 1325-1337

  Praharaj, Snigdha ^a,b   Overbey, Douglas ^a,c   Giblin, Michael F ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b University of Missouri   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

Author keywords

guanylate cyclase C; molecular imaging; PET; SPECT; uroguanylin; urokinase type plasminogen activator receptor

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID IN 111; GUANYLATE CYCLASE; GUANYLATE CYCLASE C; IBRITUMOMAB TIUXETAN; IBRITUMOMAB TIUXETAN IN 111; INDIUM 111; PENTETREOTIDE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

AMINO ACID SEQUENCE; CANCER SCINTISCANNING; COLORECTAL CANCER; DRUG RESEARCH; DRUG TARGETING; GAMMA SCINTIGRAPHY; GENE OVEREXPRESSION; HUMAN; ISOTOPE LABELING; MOLECULAR IMAGING; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW;

ANIMALS; CLINICAL TRIALS AS TOPIC; GUANYLATE CYCLASE; HUMANS; NEOPLASMS; PEPTIDE FRAGMENTS; PROGNOSIS; RADIOPHARMACEUTICALS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR;

EID: 77956327638     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.91     Document Type: Review

References (96)

1. Eberle AN, Mild G: Receptor-mediated tumor targeting with radiopeptides. Part 1. General principles and methods. J. Recept. Signal Transduct. Res. 29, 1-37 (2009).
2. van Essen M, Krenning EP, Kam BL, de Jong M, Valkema R, Kwekkeboom DJ: Peptide-receptor radionuclide therapy for endocrine tumors. Nat. Rev. Endocrinol. 5, 382-393 (2009).
3. Ansquer C, Kraeber-Bodéré F, Chatal JF: Current status and perspectives in peptide receptor radiation therapy. Curr. Pharm. Des. 15, 2453-2462 (2009).
4. Reubi JC, Maecke HR: Peptide-based probes for cancer imaging. J. Nucl. Med. 49, 1735-1738 (2008).
5. Zwanziger D, Beck-Sickinger AG: Radiometal targeted tumor diagnosis and therapy with peptide hormones. Curr. Pharm. Des. 14, 2385-2400 (2008).
6. Basu S, Kumar R, Rubello D, Fanti S, Alavi A: PET imaging in neuroendocrine tumors: current status and future prospects. Minerva Endocrinol. 33, 257-275 (2008).
7. Lewis JS, Anderson CJ: Radiometal-labeled somatostatin analogs for applications in cancer imaging and therapy. Methods Mol. Biol. 386, 227-240 (2007).
8. Smith CJ, Volkert WA, Hoffman TJ: Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl. Med. Biol. 32, 733-740 (2005).
9. Miao Y, Quinn TP: Peptide-targeted radionuclide therapy for melanoma. Crit. Rev. Oncol. Hematol. 67, 213-228 (2008).
10. Liu S: Radiolabeled multimeric cyclic RGD peptides as integrin avb3 targeted radiotracers for tumor imaging. Mol. Pharm. 3, 472-487 (2006).
11. Meyer A, Auernheimer J, Modlinger A, Kessler H: Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr. Pharm. Des. 12, 2723-2747 (2006).
12. Hockley BG, Scott PJ: An automated method for preparation of [18F]sodium fluoride for injection, USP to address the technetium- 99m isotope shortage. Appl. Radiat. Isot. 68, 117-119 (2010).
13. Jurisson S, Cutler C, Smith SV: Radiometal complexes: characterization and relevant in vitro studies. Q. J. Nucl. Med. Mol. Imaging 52, 222-234 (2008).
14. Schibli R, Schubiger PA: Current use and future potential of organometallic radiopharmaceuticals. Eur. J. Nucl. Med. Mol. Imaging 29, 1529-1542 (2002).
15. Conti PS, White C, Pieslor P, Molina A, Aussie J, Foster P: The role of imaging with 111In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry. J. Nucl. Med. 46, 1812-1818 (2005).
16. Wadas TJ, Wong EH, Weisman GR, Anderson CJ: Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr. Pharm. Des. 13, 3-16 (2007).
17. Shokeen M, Anderson CJ: Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). Acc. Chem. Res. 42, 832-841 (2009).
18. Fani M, André JP, Maecke HR: 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. Contrast Media Mol. Imaging 3, 67-77 (2008).
19. Maecke HR, André JP: 68Ga-PET radiopharmacy: a generator-based alternative to 18F-radiopharmacy. Ernst Schering Res. Found. Workshop 62, 215-242 (2007).
20. Maecke HR, Hofmann M, Haberkorn U: 68Ga-labeled peptides in tumor imaging. J. Nucl. Med. 46, S172-S178 (2005).
21. Khan MU, Khan S, El-Refaie S, Win Z, Rubello D, Al-Nahhas A: Clinical indications for gallium-68 positron emission tomography imaging. Eur. J. Surg. Oncol. 35, 561-567 (2009).
22. Miao Y, Figueroa SD, Fisher DR et al.: 203Pb-labeled a-melanocyte- stimulating hormone peptide as an imaging probe for melanoma detection. J. Nucl. Med. 49, 823-829 (2008).
23. Müller C, Schubiger PA, Schibli R: Isostructural folate conjugates radiolabeled with the matched pair 99mTc/188Re: a potential strategy for diagnosis and therapy of folate receptor-positive tumors. Nucl. Med. Biol. 34, 595-601 (2007).
24. Wang M, Caruano AL, Lewis MR, Meyer LA, VanderWaal RP, Anderson CJ: Subcellular localization of radiolabeled somatostatin analogues: implications for targeted radiotherapy of cancer. Cancer Res. 63, 6864-6869 (2003).
25. Lewis J, Laforest R, Buettner T et al.: Copper-64-diacetyl-bis(N4- methylthiosemicarbazone): an agent for radiotherapy. Proc. Natl Acad. Sci. USA 98, 1206-1211 (2001).
26. Bryan JN, Jia F, Mohsin H et al.: Comparative uptakes and biodistributions of internalizing vs. noninternalizing copper-64 radioimmunoconjugates in cell and animal models of colon cancer. Nucl. Med. Biol. 32, 851-858 (2005).
27. Zalutsky MR, Pozzi OR: Radioimmunotherapy with a-particle emitting radionuclides. Q. J. Nucl. Med. Mol. Imaging 48, 289-296 (2004).
28. Sgouros G: a-particles for targeted therapy. Adv. Drug Deliv. Rev. 60, 1402-1406 (2008).
29. Allen BJ: Clinical trials of targeted a therapy for cancer. Rev. Recent Clin. Trials 3, 185-191 (2008).
30. Dadachova E: Cancer therapy with a-emitters labeled peptides. Semin. Nucl. Med. 40, 204-208 (2010).
31. Mulford DA, Scheinberg DA, Jurcic JG: The promise of targeted a-particle therapy. J. Nucl. Med. 46, S199-S204 (2005).
32. Knór S, Sato S, Huber T et al.: Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in a-emitter therapy for disseminated ovarian cancer. Eur. J. Nucl. Med. Mol. Imaging 35, 53-64 (2008).
33. Stutchbury TK, Al-Ejeh F, Stillfried GE et al.: Preclinical evaluation of 213Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinoma. Mol. Cancer Ther. 6, 203-212 (2007).
34. Qu CF, Song EY, Li Y et al.: Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer. Clin. Exp. Metastasis 22, 575-586 (2005).
35. Song YJ, Qu CF, Rizvi SMA et al.: Cytotoxicity of PAI2, C595 and herceptin vectors labeled with the a-emitting radioisotope bismuth-213 for ovarian cancer cell monolayers and clusters. Cancer Lett. 234, 176-183 (2006).
36. Rizvi SMA, Li Y, Song YJ et al.: Preclinical studies of bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft model. Cancer Biol. Ther. 5, 386-393 (2006).
37. Barnard P, Bayly S, Betts H et al.: Towards new copper based radiopharmaceuticals. Q. J. Nucl. Med. Mol. Imaging 52, 174-184 (2008).
38. Smith SV: Sarar technology for the application of copper-64 in biology and materials science. Q. J. Nucl. Med. Mol. Imaging 52, 193-202 (2008).
39. Liu S: Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv. Drug Deliv. Rev. 60, 1347-1370 (2008).
40. Kuhn M: Function and dysfunction of mammalian membrane guanylyl cyclase receptors: lessons from genetic mouse models and implications for human diseases. Handb. Exp. Pharmacol. 191, 47-69 (2009).
41. Forte LR: Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics. Pharmacol. Ther. 104, 137-162 (2004).
42. Waldman SA, Fortina P, Surrey S, Hyslop T, Kricka LJ, Graves DJ: Opportunities for near-infrared thermal ablation of colorectal metastases by guanylyl cyclase C-targeted gold nanoshells. Future Oncol. 2, 705-716 (2006).
43. Winn B, Tavares R, Matoso A et al.: Expression of the intestinal biomarkers guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas. Hum. Pathol. 41, 123-128 (2010).
44. Frick GS, Pitari GM, Weinberg DS, Hyslop T, Schulz S, Waldman SA: Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Expert Rev. Mol. Diagn. 5, 701-713 (2005).
45. Carlson MR: Previstage GCC colorectal cancer staging test: a new molecular test to identify lymph node metastases and provide more accurate information about the stage of patients with colorectal cancer. Mol. Diagn. Ther. 13, 11-14 (2009).
46. Schulz S, Hyslop T, Haaf J et al.: A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clin. Cancer Res. 12, 4545-4552 (2006).
47. Waldman SA, Hyslop T, Schulz S et al.: Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. JAMA 301, 745-752 (2009).
48. Li P, Lin JE, Schulz S, Pitari GM, Waldman SA: Can colorectal cancer be prevented or treated by oral hormone replacement therapy? Curr. Mol. Pharmacol. 2, 285-292 (2009).
49. Li P, Lin JE, Marszlowicz GP et al.: GCC signaling in colorectal cancer: is colorectal cancer a paracrine deficiency syndrome? Drug News Perspect. 22, 313-318 (2009).
50. Lin JE, Li P, Pitari GM, Schulz S, Waldman SA: Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target. Future Oncol. 5, 509-522 (2009).
51. Mao ZB, Zhang JF, Xu Z et al.: Ectopic expression of guanylyl cyclase C in gastric cancer as a potential biomarker and therapeutic target. J. Dig. Dis. 10, 272-285 (2009).
52. Basu N, Bhandari R, Natarajan VT, Visweswariah SS: Cross talk between receptor guanylyl cyclase C and c-src tyrosine kinase regulates colon cancer cell cytostasis. Mol. Cell Biol. 29, 5277-5289 (2009).
53. Kloeters O, Friess H, Giese N, Buechler MW, Cetin Y, Kulaksiz H: Uroguanylin inhibits proliferation of pancreatic cancer cells. Scand. J. Gastroenterol. 43, 447-455 (2008).
54. Pitari GM, Lin JE, Shah FJ et al.: Enterotoxin preconditioning restores calcium-sensing receptor-mediated cytostasis in colon cancer cells. Carcinogenesis 29, 1601-1607 (2008).
55. Li P, Lin JE, Chervoneva I, Schulz S, Waldman SA, Pitari GM: Homeostatic control of the crypt-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine. Am. J. Pathol. 171, 1847-1858 (2007).
56. Li P, Schulz S, Bombonati A et al.: Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology 133, 599-607 (2007).
57. Pitari GM, Baksh RI, Harris DM, Li P, Kazerounian S, Waldman SA: Interruption of homologous desensitization in cyclic guanosine 3́,5́-monophosphate signaling restores colon cancer cytostasis by bacterial enterotoxins. Cancer Res. 65, 11129-11135 (2005).
58. Kazerounian S, Pitari GM, Shah FJ et al.: Proliferative signaling by store-operated calcium channels opposes colon cancer cell cytostasis induced by bacterial enterotoxins. J. Pharmacol. Exp. Ther. 314, 1013-1022 (2005).
59. Giblin MF, Gali H, Sieckman GL et al.: In vitro and in vivo comparison of human Escherichia coli heat-stable peptide analogues incorporating the 111In-DOTA group and distinct linker moieties. Bioconjug. Chem. 15, 872-880 (2004).
60. Wolfe HR, Waldman SA: A comparative molecular field analysis (COMFA) of the structural determinants of heat-stable enterotoxins mediating activation of guanylyl cyclase C. J. Med. Chem. 45, 1731-1734 (2002).
61. Giblin MF, Sieckman GL, Owen NK, Hoffman TJ, Forte LR, Volkert WA: Radiolabeled E. coli heat-stable enterotoxin analogs for in vivo imaging of colorectal cancer. Nucl. Instr. Meth. B. 241, 689-692 (2005).
62. Wolfe HR, Mendizabal M, Lleong E et al.: In vivo imaging of human colon cancer xenografts in immunodeficient mice using a guanylyl cyclase C-specific ligand. J. Nucl. Med. 43, 392-399 (2002).
63. Giblin MF, Sieckman GL, Watkinson LD et al.: Selective targeting of E. coli heat-stable enterotoxin analogs to human colon cancer cells. Anticancer Res. 26, 3243-3252 (2006).
64. Giblin MF, Sieckman GL, Shelton TD, Hoffman TJ, Forte LR, Volkert WA: In vitro and in vivo evaluation of 177Lu- and 90Y-labeled E. coli heat-stable enterotoxin for specific targeting of uroguanylin receptors on human colon cancers. Nucl. Med. Biol. 33, 481-488 (2006).
65. Liu D, Overbey, Watkinson L et al.: In vivo imaging of human colorectal cancer using radiolabeled analogs of the uroguanylin peptide hormone. Anticancer Res. 29, 3777-3784 (2009).
66. Tian X, Michal AM, Li P, Wolfe HR, Waldman SA, Wickstrom E: STa peptide analogs for probing guanylyl cyclase C. Biopolymers 90, 713-723 (2008).
67. Liu D, Overbey D, Watkinson LD et al.: Comparative evaluation of three 64Cu-labeled E. coli heat-stable enterotoxin analogues for PET imaging of colorectal cancer. Bioconj. Chem. 21, 1171-1176 (2010).
68. Rømer J, Nielsen BS, Ploug M: The urokinase receptor as a potential target in cancer therapy. Curr. Pharm. Des. 10, 2359-2376 (2004).
69. Ploug M: Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr. Pharm. Des. 9, 1499-1528 (2003)
70. Danø K, Behrendt N, Høyer-Hansen G et al.: Plasminogen activation and cancer. Thromb. Haemost. 93, 676-681 (2005).
71. D Alessio S, Blasi F: The urokinase receptor as an entertainer of signal transduction. Front. Biosci. 14, 4575-4587 (2009).
72. Reuning U, Sperl S, Kopitz C et al.: Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. Curr. Pharm. Des. 9, 1529-1543 (2003).
73. Ploug M, Østergaard S, Gårdsvoll H et al.: Peptide-derived antagonists of the urokinase receptor: affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry 40, 12157-12168 (2001).
74. Magdolen V, Bürgle M, de Prada NA, Schmiedeberg N, Riemer C, Schroeck F: Cyclo(19,31)[D-Cys(19)]-uPA(19-31) is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87). Biol. Chem. 382, 1197-1205 (2001).
75. Lin L, Gårdsvoll H, Huai Q, Huang M, Ploug M: Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy. J. Biol. Chem. 285, 10982-10992 (2010).
76. Huai Q, Mazar AP, Kuo A et al.: Structure of human urokinase plasminogen activator in complex with its receptor. Science 311, 656-659 (2006).
77. Llinas P, Le Du MH, Gårdsvoll H et al.: Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J. 24, 1655-1663 (2005).
78. Knór S, Sato S, Huber T, Morgenstern A et al.: Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in a-emitter therapy for disseminated ovarian cancer. Eur. J. Nucl. Med. Mol. Imaging 35, 53-64 (2008).
79. Li ZB, Niu G, Wang H et al.: Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by microPET. Clin. Cancer Res. 14, 4758-4766 (2008).
80. Liu D, Overbey D, Watkinson L, Giblin MF: Synthesis and characterization of an 111In-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR). Bioconjug. Chem. 20, 888-894 (2009).
81. Magdolen V, Bürgle M, de Prada NA, Schmiedeberg N, Riemer C, Schroeck F: Cyclo(19,31)[D-Cys(19)]-uPA(19-31) is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87). Biol. Chem. 382, 1197-1205 (2001).
82. Schmiedeberg N, Schmitt M, Rol C, Truffault V, Sukopp M, Bürgle M: Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics. J. Med. Chem. 45, 4984-4994 (2002).
83. Armstrong AF, Lemon JA, Czorny SK, Singh G, Valliant JF: Evaluation of single amino acid chelate derivatives and regioselective radiolabelling of a cyclic peptide for the urokinase plasminogen activator receptor. Nucl. Med. Biol. 36, 907-917 (2009).
84. Stutchbury TK, Al-Ejeh F, Stillfried GE et al.: Preclinical evaluation of 213Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinoma. Mol. Cancer Ther. 6, 203-212 (2007).
85. Song YJ, Qu CF, Rizvi SMA et al.: Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the a-emitting radioisotope bismuth-213 for ovarian cancer cell monolayers and clusters. Cancer Lett. 234, 176-183 (2006).
86. Rizvi SMA, Li Y, Song YJ et al.: Preclinical studies of bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft model. Cancer Biol. Ther. 5, 386-393 (2006).
87. Law B, Curino A, Bugge TH, Weissleder R, Tung CH: Design, synthesis, and characterization of urokinase plasminogen-activator-sensitive near-infrared reporter. Chem. Biol. 11, 99-106 (2004).
88. Hsiao JK, Law B, Weissleder R, Tung CH: In vivo imaging of tumor associated urokinase-type plasminogen activator activity. J. Biomed. Opt. 11, 34013 (2006).
89. Law B, Weissleder R, Tung CH: Protease-sensitive fluorescent nanofibers. Bioconjug. Chem. 18, 1701-1704 (2007).
90. Law B, Tung CH: Structural modification of protease inducible preprogrammed nanofiber precursor. Biomacromolecules 9, 421-425 (2008).
91. Koo OM, Rubinstein I, Onyuksel H: Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine 1, 193-212 (2005).
92. McCarthy JR, Weissleder R: Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv. Drug Deliv. Rev. 60, 1241-1251 (2008).
93. Michalet X, Pinaud FF, Bentolila LA et al.: Quantum dots for live cells, in vivo imaging, and diagnostics. Science 307, 538-544 (2005).
94. Liu Y, Miyoshi H, Nakamura M: Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int. J. Cancer. 120, 2527-2537 (2007).
95. Yang L, Peng XH, Wang YA et al.: Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin. Cancer Res. 15, 4722-4732 (2009).
96. Yang L, Mao H, Cao Z et al.: Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles. Gastroenterology 136, 1514-1525 (2009)